Without naming the company, it said it has secured a commercial licence for the intellectual property necessary to commercialise GLP-1 drugs - a class of highly effective diabetes and obesity drugs - following the expiry of the originator product patents.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/Gsj7Kea
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment